Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study

BACKGROUND: The effectiveness of combining anti-programmed cell death protein 1 (PD-1) and chemotherapy has been evaluated as superior to that of chemotherapy alone in the patients with advanced epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-resistant non-small cell lung cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Chang, Zhang, Yiruo, Liu, Pingping, Mei, Xinkuan, Cheng, Gang, Pang, Jingdan, Chen, Sheng, Xu, Jianping, Malhotra, Jyoti, Qian, Hesheng, Du, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636450/
https://www.ncbi.nlm.nih.gov/pubmed/37969256
http://dx.doi.org/10.21037/jtd-23-1399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636450/
https://www.ncbi.nlm.nih.gov/pubmed/37969256
http://dx.doi.org/10.21037/jtd-23-1399

Ejemplares similares